You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

~ Buy the ALUNBRIG (brigatinib) Drug Profile, 2024 PDF Report in the Report Store ~

ALUNBRIG Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Alunbrig, and what generic alternatives are available?

Alunbrig is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are four patents protecting this drug.

This drug has ninety patent family members in thirty-nine countries.

The generic ingredient in ALUNBRIG is brigatinib. One supplier is listed for this compound. Additional details are available on the brigatinib profile page.

DrugPatentWatch® Generic Entry Outlook for Alunbrig

Alunbrig was eligible for patent challenges on April 28, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 10, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALUNBRIG?
  • What are the global sales for ALUNBRIG?
  • What is Average Wholesale Price for ALUNBRIG?
Summary for ALUNBRIG
International Patents:90
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 61
Clinical Trials: 10
Patent Applications: 416
Drug Prices: Drug price information for ALUNBRIG
What excipients (inactive ingredients) are in ALUNBRIG?ALUNBRIG excipients list
DailyMed Link:ALUNBRIG at DailyMed
Drug patent expirations by year for ALUNBRIG
Drug Prices for ALUNBRIG

See drug prices for ALUNBRIG

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ALUNBRIG
Generic Entry Date for ALUNBRIG*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALUNBRIG

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Intergroupe Francophone de Cancerologie ThoraciquePhase 2
Princess Maxima Center for Pediatric OncologyPhase 1/Phase 2
TakedaPhase 1/Phase 2

See all ALUNBRIG clinical trials

Pharmacology for ALUNBRIG

US Patents and Regulatory Information for ALUNBRIG

ALUNBRIG is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALUNBRIG is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ALUNBRIG

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylp- iperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Phosphorous derivatives as kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Phosphorus derivatives as kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Methods for inhibiting cell proliferation in ALK-driven cancers
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

FDA Regulatory Exclusivity protecting ALUNBRIG

TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
Exclusivity Expiration: ⤷  Sign Up

FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-003 Oct 2, 2017 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa ALUNBRIG brigatinib TABLET;ORAL 208772-002 Apr 28, 2017 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ALUNBRIG

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Takeda Pharma A/S Alunbrig brigatinib EMEA/H/C/004248
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib.
Authorised no no no 2018-11-22
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ALUNBRIG

When does loss-of-exclusivity occur for ALUNBRIG?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15335950
Patent: Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 65169
Patent: FORMES CRISTALLINES DE 5-CHLORO-N4-[2-(DIMETHYLPHOSPHORYL)PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N4-[2-(DIMETHYLPHOSPHORYL)PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 17000979
Patent: Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
Estimated Expiration: ⤷  Sign Up

China

Patent: 7108559
Patent: 5‑氯‑N4‑[2‑(二甲基磷酰基)苯基]‑N2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]嘧啶‑2,4‑二胺的晶形 (Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Patent: 1825717
Patent: 5-氯-N4-[2-(二甲基磷酰基)苯基]-N2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形 (Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Patent: 1888368
Patent: 5-氯-N4-[2-(二甲基磷酰基)苯基]-N2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形 (Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 17004714
Patent: Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 170146
Patent: FORMAS CRISTALINAS DE 5-CLORO-N4-[-2-(DIMETILFOSFORIL)FENIL]-N2-{2-METOXI-4-[4-(4-METILPIPERAZIN-1-YL)PIPERIDIN-1-IL]PIRIMIDINA-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0201343
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 23295
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 09647
Estimated Expiration: ⤷  Sign Up

Dominican Republic

Patent: 017000101
Patent: FORMAS CRISTALINAS DE 5-CLORO-N4-[2-(DIMETILFOSFORIL)FENIL]-N2-{2-METOXI-4-[4-(4-METILPIPERAZIN-1-IL)PIPERIDIN-1-IL]PIRIMIDINA-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 17030878
Patent: FORMAS CRISTALINAS DE 5-CLORO-N4-[2-(DIMETILFOSFORIL)FENIL]-N2-{2-METOXI-4-[4-(4-METILPIPERAZIN-1-IL)PIPERIDIN-1-IL]PIRIMIDINA-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 5145
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N4-[2-(ДИМЕТИЛФОСФОРИЛ)ФЕНИЛ]-N2-{2-МЕТОКСИ-4-[4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛ)ПИПЕРИДИН-1-ИЛ]ФЕНИЛ}ПИРИМИДИН-2,4-ДИАМИНА (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL)PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 1790892
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N4-[2-(ДИМЕТИЛФОСФОРИЛ)ФЕНИЛ]-N2-{2-МЕТОКСИ-4-[4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛ)ПИПЕРИДИН-1-ИЛ]}ПИРИМИДИН-2,4-ДИАМИНА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 09647
Patent: FORMES CRISTALLINES DE 5-CHLORO-N4- [-2- (DIMÉTHYLPHOSPHORYL) PHÉNYL]-N2- {2-MÉTHOXY-4- [4- (4-MÉTHYLPIPÉRAZIN-1-YL) PIPÉRIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 60618
Patent: FORMES CRISTALLINES DE 5-CHLORO-N4-[-2-(DIMÉTHYLPHOSPHORYL) PHÉNYL]-N2-{2-MÉTHOXY-4-[4-(4-MÉTHYLPIPERAZINE-1-YL) PIPÉRIDINE-1-YL]PYRIMIDINE-2,4-DIAMINE (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 51693
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 1818
Patent: צורות גבישיות של 5- כלורו-אן 4- [2-(דימתילפוספוריל)פניל]-אן2-{2-מתוקסי-4-[4-(4-מתילפיפראזין-1-איל) פיפרידין-1-איל]פירימידין-2-4-דיאמין (Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Patent: 9910
Patent: צורות גבישיות של 5- כלורו-אן 4- [2-(דימתילפוספוריל)פניל]-אן2-{2-מתוקסי-4-[4-(4-מתילפיפראזין-1-איל) פיפרידין-1-איל]פירימידין-2-4-דיאמין (Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2- {2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 33072
Estimated Expiration: ⤷  Sign Up

Patent: 17535538
Patent: 5−クロロ−N4−[2−(ジメチルホスホリル)フェニル]−N2−{2−メトキシ−4−[4−(4−メチルピペラジン−1−イル)ピペリジン−1−イル]ピリミジン−2,4−ジアミンの結晶形態
Estimated Expiration: ⤷  Sign Up

Patent: 20063276
Patent: 5−クロロ−N4−[2−(ジメチルホスホリル)フェニル]−N2−{2−メトキシ−4−[4−(4−メチルピペラジン−1−イル)ピペリジン−1−イル]フェニル}ピリミジン−2,4−ジアミンの結晶形態 (CRYSTAL FORM OF 5-CHLORO-N4-[2-(DIMETHYL PHOSPHORYL)PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZINE-1-YL)PIPERIDINE-1-YL]PHENYL}PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 09647
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 2216
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 17005120
Patent: FORMAS CRISTALINAS DE 5-CLORO-N4-[-2-(DIMETILFOSFORIL) FENIL]-N2-{2-METOXI-4-[4-(4-METILPIPERAZIN-1-IL)PIPERIDIN-1-IL] PIRIMIDIN-2,4-DIAMINA. (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 0940
Patent: Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{ 2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 171344
Patent: FORMAS CRISTALINAS DE 5-CLORO-N4-[2-(DIMETILFOSFORIL)FENIL]-N2-{2-METOXI-4-[4-(4-METILPIPERAZIN-1-IL)PIPERIDIN-1-IL]PIRIMIDINA-2,4-DIAMINA
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 017500732
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 09647
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 737
Patent: KRISTALNI OBLICI 5-HLORO-N4-[-2-(DIMETILFOSFORIL)FENIL]-N2-{2-METOKSI-4-[4-(4-METILPIPERAZIN-1-IL)PIPERIDIN-1-IL]PIRIMIDIN-2,4-DIAMINA (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201702980Q
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 09647
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1702737
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL}PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2331856
Estimated Expiration: ⤷  Sign Up

Patent: 170072905
Patent: 결정 형태의 5-클로로-N4-[2-페닐]-N2-{2-메톡시-4-[4-피페리딘-1-일]피리미딘-2,4-디아민 (5--N4-[2-]-N2-2--4-[4-4--1--1-]-24-CRYSTALLINE FORMS OF 5-CHLORO-N4-[2-DIMETHYLPHOSPHORYLPHENYL]-N2-2-METHOXY-4-[4-4-METHYLPIPERAZIN-1-YLPIPERIDIN-1-YL]PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Patent: 210142781
Patent: 결정 형태의 5-클로로-N4-[2-페닐]-N2-{2-메톡시-4-[4-피페리딘-1-일]피리미딘-2,4-디아민 (5--N4-[2-]-N2-2--4-[4-4--1--1-]-24-CRYSTALLINE FORMS OF 5-CHLORO-N4-[2-DIMETHYLPHOSPHORYLPHENYL]-N2-2-METHOXY-4-[4-4-METHYLPIPERAZIN-1-YLPIPERIDIN-1-YL]PYRIMIDINE-24-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 13726
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 17000157
Patent: CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 9794
Patent: КРИСТАЛІЧНА ФОРМА 5-ХЛОР-N4-[2-(ДИМЕТИЛФОСФОРИЛ)ФЕНІЛ]-N2-{2-МЕТОКСИ-4-[4-(4-МЕТИЛПІПЕРАЗИН-1-ІЛ)ПІПЕРИДИН-1-ІЛ]}ПІРИМІДИН-2,4-ДІАМІНУ (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PYRIMIDINE-2,4-DIAMINE)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ALUNBRIG around the world.

Country Patent Number Title Estimated Expiration
Japan 2017186345 キナーゼ阻害剤としてのリン誘導体 (PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS) ⤷  Sign Up
Denmark 3209647 ⤷  Sign Up
Eurasian Patent Organization 035145 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 5-ХЛОР-N4-[2-(ДИМЕТИЛФОСФОРИЛ)ФЕНИЛ]-N2-{2-МЕТОКСИ-4-[4-(4-МЕТИЛПИПЕРАЗИН-1-ИЛ)ПИПЕРИДИН-1-ИЛ]ФЕНИЛ}ПИРИМИДИН-2,4-ДИАМИНА (CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL)PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL)PIPERIDIN-1-YL]PYRIMIDINE-2,4-DIAMINE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALUNBRIG

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2300013 2019024 Norway ⤷  Sign Up PRODUCT NAME: BRIGATINIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/18/1264 20181218
2300013 PA2019510,C2300013 Lithuania ⤷  Sign Up PRODUCT NAME: BRIGATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1264 20181122
2300013 132019000000069 Italy ⤷  Sign Up PRODUCT NAME: BRIGATINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ALUNBRIG); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1264, 20181126
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.